Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
When determining treatment approach to newly-diagnosed follicular lymphoma (e.g. watchful waiting vs chemotherapy), do you take the intensity of the SUV measurements on PET into account?
The short answer is NO. The SUV value does not inform the decision between a "watch and wait" vs. chemotherapy approach. Overreliance on SUV values in newly diagnosed follicular lymphoma is not recommended. The intensity of SUV measurement may, however, aid in locating a site for biopsy. For example...
Should we continue to offer consolidative radiation for early stage, non-bulky Hodgkin's disease for individuals who have had a complete response (Deauville 1 or 2) after chemotherapy by PET?
The RAPID study was a non-inferiority trial. This requires a small editorial. Non-inferiority trials are designed to test that one approach is "not worse" than an accepted standard. However, in essence you are testing that one approach is "not unacceptably worse" than an accepted standard, because t...
How do you decide on the modality of consolidative treatment after a CR in primary CNS lymphoma patients treated with a high-dose methotrexate regimen?
Unless there are contraindications to autologous transplant I favor consolidation with autologous transplant. The long term complications of whole brain XRT include significant neurocognitive deficits. These approaches are rough equal with regards to efficacy.
Is there any data to support to use of Brentuximab in the up-front setting in the treatment of Hodgkin lymphomas?
Currently, Brentuximab vedotin is only approved in Hodgkin lymphoma 1) following failure of 2 multi-agent regimens or ASCT and 2) for post-ASCT maintenance. However, there are several ongoing phase II and III trials in both the US and EU examining Brentuximab vedotin in the up-front setting. The lar...
How do you manage a patient who has developed a symptomatic pleural effusion while on dasatinib?
A variety of approaches to dasatinib-induced pleural effusion are possible. It is common to rechallenge the patient with dasatinib once the effusion resolves. You can rechallenge with the standard dose if the grade of the initial effusion was grade 1 or 2 (by CTAE grading) or at 50 mg if the effusio...
How do you approach maintenance therapy for relapsed follicular lymphoma?
In general, patients who received 2 years of maintenance rituximab in first-line settings are unlikely to benefit from more maintenance rituximab in second-line. This is especially true if relapse occurs within 24 months of first-line therapy.A meta-analysis (JNCI 2011) did show a small benefit in o...
What is the risk of breast cancer that you quote to young women with early stage Hodgkin's lymphoma receiving involved field/site radiation therapy?
The risk depends on many different factors, including the amount of breast exposure to radiation, age of the patient, chemotherapy regimen, etc. Patients at greatest risk are likely those with axillary involvement who are < 30, where a large portion of their breast maybe unintentionally irradiated. ...
Can we ever observe newly diagnosed chronic phase CML patients and not immediately start them on therapy?
I can't think of a situation that would justify a "watch and wait" approach to CML. There are a number of effective therapies. Even if a patient has side effects from one TKI, there are others to choose from. What justification is there for not using an effective therapy? What is the rationale? Da...
Has the combination of daratumumab, bortezomib, and dexamethasone been tried for the treatment of plasma cell leukemia?
Do you ever discontinue ibrutinib in patients with CLL who have a good response?
For patients who are responding well to ibrutinib and tolerating the drug well, I do not discontinue ibrutinib. The clinical trials of single agent BTK inhibitors have all continued therapy indefinitely, which is a logical approach considering that very few will attain minimal residual disease negat...